SAB Biotherapeutics, Inc. (SABS)
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.
It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.
In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza.
Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection.
SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 56 |
CEO | Samuel J. Reich |
Contact Details
Address: 2100 East 54th Street North Sioux Falls, South Dakota 57104 United States | |
Phone | 605-679-6980 |
Website | sabbiotherapeutics.com |
Stock Details
Ticker Symbol | SABS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001833214 |
CUSIP Number | 78397T103 |
ISIN Number | US78397T2024 |
Employer ID | 85-3899721 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Samuel J. Reich | Chief Executive Officer and Executive Chairman |
Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
Christine E. Hamilton M.B.A. | Co-Founder and Independent Director |
Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
Dr. Edward D. Hamilton D.V.M. | Co-Founder and Board Observer |
Michael George King Jr. | Executive Vice President and Chief Financial Officer |
Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
Dr. Carlos N. Carillo Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 8, 2024 | 8-K | Current Report |
Feb 23, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 2, 2024 | 8-K | Current Report |
Jan 26, 2024 | 8-K | Current Report |
Jan 26, 2024 | 424B5 | Filing |
Jan 25, 2024 | 8-K | Current Report |
Jan 19, 2024 | 8-K | Current Report |